The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide

Background: In patients with bone metastatic castration-resistant prostate cancer (bmCRPC) on systemic treatment, it is difficult to differentiate between continuous rise of prostate specific antigen (PSA) representing progression, and PSA-surge, which is followed by clinical response or stable dise...

Full description

Bibliographic Details
Main Authors: Boegemann, M. (Author), Poteska, R. (Author), Rahbar, K. (Author), Schlack, K. (Author), Schrader, A.J (Author), Semjonow, A. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Online Access:View Fulltext in Publisher